Ethics approval and consent to participate
MINOR, AFRICAN TRYPANOSOMIASIS
The study in Guinea was part of the multi-country diagnostic clinical trial “Diagnostic tools for human African trypanosomiasis elimination and clinical trials work package 2, passive case detection” (DiTECT-HAT-WP2), registered on ClinicalTrials.Gov under identifier NCT03356665. Before initiation of the study, DiTECT-HAT-WP2 received ethical clearance from the Advisory Committee on Deontology and Ethics of the French National Institute for Research on Sustainable Development (plenary meeting of 17–20 October 2016), of the Institutional Review Board of the Institute of Tropical Medicine in Antwerp Belgium (reference 1133/16), and of the Ethics Committee of the University of Antwerp (Belgian registration number B300201730927). In Guinea, DiTECT-HAT-WP2 was approved by the Comité National d’Ethique pour la Recherche en Santé (CNERS, reference 025/CNERS/17). Potential study participants were informed how and why the study was carried out, and gave their written informed consent before inclusion in the study. For minor participants, an assent was obtained and written informed consent was provided by the parents or legal guardians. All clinical investigations were conducted according to the Declaration of Helsinki.